Curosurf — Competitive Intelligence Brief

Curosurf (PORACTANT ALFA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Surfactant [EPC]. Area: Respiratory.

marketed Surfactant [EPC] Respiratory

Target snapshot

Curosurf (PORACTANT ALFA) — Chiesi Usa Inc. Curosurf works by reducing the surface tension in the lungs, allowing for easier breathing and improving oxygenation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Curosurf TARGET	PORACTANT ALFA	Chiesi Usa Inc	marketed	Surfactant [EPC]		1999-01-01
Infasurf	CALFACTANT	ONY	marketed	Surfactant [EPC]		1998-01-01
Survanta	BERACTANT	AbbVie	marketed	Surfactant [EPC]		1991-01-01
Colace	docusate sodium	Generic (multiple manufacturers)	marketed	Stool softener (surfactant laxative)	N/A (surfactant mechanism)	1955-01-01
Poractant alfa instillation	Poractant alfa instillation	Poznan University of Medical Sciences	marketed	Pulmonary surfactant replacement	Pulmonary surfactant (lipid and protein complex)
Poractant alfa (Curosurf®)	Poractant alfa (Curosurf®)	Chiesi Farmaceutici S.p.A.	marketed	Pulmonary surfactant replacement therapy
Bolus surfactant	Bolus surfactant	Zekai Tahir Burak Women's Health Research and Education Hospital	marketed	Pulmonary surfactant replacement therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Surfactant [EPC] class)

1. AbbVie · 1 drug in this class
2. Chiesi Usa Inc · 1 drug in this class
3. ONY · 1 drug in this class